NerveAide

Cover Block

PUBLIC

Company	NerveAide
Tagline	Wearable neuro-rehab solutions combining FES/NMES, smart sensors, and app guidance for mobility and independence. [NerveAide]
Headquarters	Toronto, Canada
Founded	2017 [F6S]
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+) [NerveAide]
Funding Label	Seed

Links

PUBLIC

• Website: https://nerveaide.com/
• LinkedIn: https://fr.linkedin.com/company/nerveaide

Executive Summary

PUBLIC

NerveAide is a Toronto-based neurotechnology company building a suite of clinician-guided wearable devices aimed at restoring mobility for patients with central nervous system disorders, a market segment characterized by high clinical need and limited at-home options [NerveAide, retrieved 2024]. The company, founded in 2017, has developed a modular product line that combines functional electrical stimulation (FES/NMES), smart sensors, and a companion app, positioning its hardware-plus-software model to address rehabilitation from clinic to home [NerveAide, retrieved 2024]. Its founding team includes Pouria Mireshghi as CEO, with co-founder Elham Mireshghi bringing an anthropological perspective, though specific clinical or engineering backgrounds for the founders are not detailed in public profiles [LinkedIn, retrieved 2024] [LinkedIn, retrieved 2026].

NerveAide has participated in prominent Canadian accelerators, including Creative Destruction Lab and MaRS, and closed a Seed round in October 2022, though the amount and lead investor remain undisclosed [Tracxn, 2025]. The primary challenge for investors over the next 12-18 months will be validating commercial traction and clinical adoption, as public information currently consists largely of company-authored materials without third-party validation of customer deployments or partnership announcements [NerveAide, retrieved 2024]. The company's ability to transition from accelerator participant to a commercially scaled entity with verifiable revenue and user data will be the critical inflection point.

Data Accuracy: YELLOW -- Core product and company description are confirmed via primary website. Founder identities are partially corroborated via LinkedIn. Seed round date is confirmed via a single aggregator; amount and lead are not public.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed

Company Overview

PUBLIC

NerveAide was founded in 2017 in Toronto, Canada, positioning itself at the intersection of neurotechnology and rehabilitation hardware [F6S, retrieved 2024]. The company's public narrative centers on a mission to restore movement and rebuild lives by making clinician-guided neurotechnology accessible, moving from clinical settings into the home [NerveAide Mission & Impact, retrieved 2024]. While the founding story is not detailed in public sources, the company describes itself as being established by a group of entrepreneurs, engineers, and neurologists [NerveAide, retrieved 2024].

Key operational milestones are primarily evidenced by the company's participation in prominent Canadian accelerators. NerveAide is an alumnus of both the Creative Destruction Lab (CDL) and MaRS accelerator programs, which typically provide structured mentorship and early-stage validation [Tracxn, retrieved 2026]. The company closed a Seed funding round in October 2022, though the amount and lead investor remain undisclosed [Tracxn, retrieved 2026]. Since its founding, NerveAide has developed and publicly launched a portfolio of at least six distinct wearable medical devices targeting conditions from foot drop to sleep apnea [NerveAide, retrieved 2024].

Data Accuracy: YELLOW -- Founding year and accelerator participation are corroborated; founding team details and funding specifics rely on a single source.

Product and Technology

MIXED NerveAide’s product suite is built on a consistent technical foundation, targeting a specific clinical workflow. The company designs wearable neuro-rehabilitation devices that combine functional electrical stimulation (FES/NMES), integrated smart sensors, and a companion mobile application for guidance [NerveAide, retrieved 2024]. This approach aims to translate a clinician-prescribed therapy from a clinical setting into a user-managed routine at home.

The portfolio is segmented by anatomical application and condition, suggesting a modular strategy for patient pathways. Key products include:

• NeStim. A dual-channel device providing both neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS), with app guidance, USB-C charging, and Bluetooth® 5 connectivity for muscle activation and pain relief [NerveAide, retrieved 2024].
• NEwalk+. A system designed for individuals with foot drop and thigh weakness, a common impairment following stroke or neurological injury [NerveAide, retrieved 2024].
• NeArm & NeGrasp. Targeted solutions for upper-limb rehabilitation, supporting reach, elbow control, and hand function [NerveAide, retrieved 2024].
• NeBack & NeBow. Devices focused on postural support for the trunk and leg muscle strengthening for bow-leg alignment, respectively [NerveAide, retrieved 2024].
• neSNORE®. A departure from the mobility-focused line, this is a device indicated for snoring and mild sleep apnea relief [Seniors by NerveAide, retrieved 2026].

The technology stack appears to integrate low-energy wireless connectivity, sensor data processing, and a software layer for parameter personalization and progress tracking, all described as central to the user experience [NerveAide, retrieved 2024]. The company states its products are clinician-guided and emphasizes quality and regulatory standards, though specific regulatory clearances (e.g., FDA, Health Canada) are not detailed in public materials [NerveAide].

Data Accuracy: YELLOW -- Product details are confirmed from the company's own website, but technical specifications and regulatory status lack independent verification.

Market Research

PUBLIC The market for neuro-rehabilitation technology is being reshaped by a convergence of demographic pressures, clinical evidence, and a policy-driven shift toward cost-effective home care. NerveAide operates at the intersection of several large and growing healthcare segments, though the company's specific market penetration is not publicly quantified.

A precise TAM for NerveAide's suite of functional electrical stimulation (FES) devices is not available from public sources. The company's addressable market can be approximated by examining the prevalence of the neurological conditions it targets. For instance, stroke is a leading cause of serious long-term disability in the United States, with an estimated annual incidence of nearly 800,000 cases [CDC]. Multiple sclerosis affects close to 1 million people in the U.S. alone [National MS Society]. The global market for physical rehabilitation equipment, a broader category, was valued at approximately $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 6% through 2030, driven by an aging population and rising chronic disease burden [Grand View Research, 2023].

Key demand drivers extend beyond patient demographics. There is a well-documented shortage of physical therapists and rehabilitation specialists, creating pressure to extend clinical resources through technology [American Physical Therapy Association]. Concurrently, payers are increasingly incentivizing home-based care and value-based outcomes, which favors durable medical equipment designed for patient self-management. The clinical evidence base for neurostimulation in motor recovery continues to expand, supporting its integration into standard care pathways for conditions like foot drop post-stroke [Journal of NeuroEngineering and Rehabilitation].

Adjacent and substitute markets include traditional orthotics and braces, pharmaceutical interventions for spasticity, and more invasive surgical options. The competitive pressure comes from the entrenched reimbursement pathways for these alternatives, even as FES devices aim to demonstrate superior long-term outcomes and patient adherence. Regulatory forces are central; devices like those offered by NerveAide typically require clearance from bodies like Health Canada or the U.S. Food and Drug Administration (FDA) as Class II medical devices, a process that defines time-to-market and claims substantiation.

Metric	Value
Global Rehab Equipment Market 2022	15 $B
Projected CAGR 2023-2030	6 %
U.S. Stroke Incidence (annual)	0.8 million patients
U.S. MS Prevalence	1 million patients

The sizing data, drawn from analogous market reports and public health statistics, illustrates the substantial underlying patient population and total addressable market for rehabilitation solutions. The growth projection for the broader equipment category suggests a stable, non-cyclical tailwind, though it does not isolate the specific growth rate for advanced neurostimulation devices.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous third-party reports and public health data; company-specific SAM/SOM is not publicly available.

Competitive Landscape

MIXED NerveAide operates in a crowded and fragmented market for neuro-rehabilitation technology, where its primary challenge is not a single direct rival but a collection of established incumbents and adjacent substitutes that dominate different segments of patient care.

Without a named competitor in the public record, a direct comparison table is not possible. The competitive analysis must therefore be built from an understanding of the broader market structure.

The competitive map can be broken into three primary segments. First, incumbent medical device giants like Ottobock (with its Walkaide FES system) and Bioness dominate the prescription-grade, insurance-reimbursed market for foot drop and upper-limb rehabilitation [PUBLIC]. These companies have deep clinical validation, established distribution through durable medical equipment (DME) channels, and long-standing relationships with physiatrists and hospitals. Second, a wave of challenger startups focusing on digital therapeutics and at-home recovery, such as Hinge Health (for musculoskeletal pain) and Kaia Health, are expanding their scope into adjacent neurological conditions, leveraging software-first models and direct-to-consumer marketing [PUBLIC]. Third, adjacent substitutes include traditional physical therapy services, over-the-counter TENS units for pain management, and consumer wellness wearables that track mobility metrics but lack therapeutic stimulation.

NerveAide’s defensible edge today appears to be its product breadth and modularity. While incumbents like Ottobock offer deep vertical solutions for specific indications, NerveAide’s portfolio spans foot drop (neWALK+), upper limb (NeArm), leg strengthening (NeLeg), posture (NeBack), and even sleep support (neSNORE) [NerveAide]. This approach of a “modular pathway,” as described on its website, allows for cross-selling within a single patient’s evolving rehab journey, a strategy less common among the more specialized legacy players. However, this edge is perishable. It relies on maintaining a technological and usability advantage across multiple product lines without the sales force or reimbursement footprint of the incumbents. Durability will depend on securing regulatory clearances and building a body of clinical evidence for each device, a costly and time-intensive process.

The company is most exposed in two key areas. It lacks the reimbursement infrastructure that is critical for adoption in the core neuro-rehab patient population, who often rely on insurance coverage for expensive medical devices. Incumbents have dedicated teams navigating Medicare and private payer policies. Furthermore, NerveAide does not appear to own a direct clinical channel. Its website emphasizes being “clinician-guided,” but without public partnerships with major hospital networks or rehabilitation clinics, the route to the prescribing physician remains unclear and vulnerable to being blocked by established vendor relationships.

The most plausible 18-month competitive scenario involves market segmentation hardening. A “winner” in this period could be a startup that successfully partners with a large telehealth provider or insurer to bundle its digital neuro-rehab solution, bypassing traditional DME channels altogether. A “loser” would be a hardware-focused company like NerveAide if it fails to secure a key distribution partnership or a pivotal clinical study, leaving it stranded with a broad product catalog but no efficient way to reach patients at scale. Its fate likely hinges on demonstrating not just product capability, but also a repeatable and funded commercial motion.

Opportunity

PUBLIC

If NerveAide can successfully navigate the regulatory and commercial path to becoming a standard-of-care tool in neurorehabilitation, the prize is a durable position in a multi-billion-dollar market for chronic condition management.

The headline opportunity is to become the category-defining, clinician-prescribed platform for at-home neurorehabilitation, moving beyond a collection of devices to an integrated, data-driven care pathway. The cited evidence suggests this outcome is reachable because the company has already articulated a modular product architecture designed for expansion, with distinct devices for foot drop, upper-limb function, posture, and sleep support [NerveAide, retrieved 2024]. This indicates a strategic move from selling single-point solutions to owning the patient journey across multiple rehabilitation needs, a classic platform-building approach in medical devices. The company's focus on clinician guidance and app-based personalization is a direct response to the critical need for supervised, scalable home care in neurology [NerveAide About, retrieved 2024].

Growth Scenarios

The company's path to scale likely hinges on one of three concrete, non-mutually exclusive routes.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory & Reimbursement Win	NeWalk+ or a similar flagship device receives a specific CPT code or favorable coverage decision from a major U.S. payer, unlocking insurance reimbursement.	Publication of a positive clinical outcomes study conducted with a research hospital.	The product is explicitly designed for clinical use and home transition [NerveAide, retrieved 2024]. FES for foot drop is an established therapeutic category with existing reimbursement pathways for competitors.
Vertical Integration with Large Health System	A major integrated delivery network (IDN) adopts the NerveAide suite as its standard post-acute neurorehab toolkit, deploying it across outpatient clinics and home health.	A successful multi-site pilot program with a named health system partner.	The company's messaging is heavily oriented toward clinician guidance and the clinic-to-home continuum, suggesting a built-in channel strategy [NerveAide, retrieved 2024].
Consumer-DTC Breakthrough	The NeStim device gains traction as a direct-to-consumer wellness product for muscle recovery and pain relief, funding the core medical business.	A strategic marketing partnership with a major athletic retailer or wellness influencer network.	NeStim is marketed for both clinical tone management and drug-free pain relief, straddling the medical and wellness markets [NerveAide, retrieved 2024].

What compounding looks like is a data and distribution flywheel. Each new clinical deployment generates proprietary data on stimulation parameters and patient progress, which can be used to refine algorithms and demonstrate superior outcomes,a key asset for securing further reimbursement and clinical adoption. Furthermore, a clinician who prescribes NeWalk+ for foot drop becomes a natural candidate to prescribe NeArm for a patient's upper-limb needs, or NeStim for spasticity management. This cross-selling within a trusted platform reduces customer acquisition cost and increases lifetime value. The company's website structure, organizing products by both category and use case, reflects this intended expansion logic [NerveAide, retrieved 2024].

The size of the win, while speculative, can be framed by looking at comparable exits and market valuations. Public peers in the neuromodulation and rehabilitation robotics space, such as BioNexus (acquired) or smaller public medtech firms, have historically traded at revenue multiples reflective of their growth in chronic care markets. A more direct comparable might be the market creation story of continuous glucose monitors (CGMs) in diabetes, which transformed from a niche product to a multi-billion-dollar standard of care. For NerveAide, if the "Regulatory & Reimbursement Win" scenario plays out for its foot drop system, it could capture a meaningful portion of the addressable market for gait rehabilitation, which numbers in the hundreds of thousands of new patients annually in North America alone. At an assumed average selling price for a medical device system, this suggests a revenue potential in the tens of millions for a single product line. A platform owning multiple such lines could support a valuation significantly higher. This is a scenario-based illustration, not a forecast.

Data Accuracy: YELLOW -- The opportunity analysis is built on the company's stated product strategy and market positioning, which is well-documented. The growth scenarios and comps are extrapolations from this foundation, as no public data on commercial traction, clinical studies, or partnerships was available to corroborate.

Sources

PUBLIC

1. [NerveAide, retrieved 2024] NerveAide - Helping people regain mobility and independence. | https://nerveaide.com/

2. [NerveAide About, retrieved 2024] NerveAide About | https://nerveaide.com/en/about

3. [NerveAide Mission & Impact, retrieved 2024] NerveAide Mission & Impact | https://nerveaide.com/en/mission-impact

4. [F6S, retrieved 2024] F6S profile | https://www.f6s.com/company/nerveaide

5. [LinkedIn, retrieved 2024] Pouria Mireshghi - Co-Founder and CEO at NerveAide | https://fr.linkedin.com/in/mireshghi

6. [Tracxn, 2025] Nerve - 2025 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/nerveaide

7. [LinkedIn, retrieved 2026] Elham Mireshghi - Private Clinic | https://www.linkedin.com/in/elham-mireshghi/

8. [Seniors by NerveAide, retrieved 2026] Seniors by NerveAide | Wearable FES & adjuncts for safer mobility, posture support & daily confidence NerveAide | https://nerveaide.com/en/seniors

9. [CDC] Centers for Disease Control and Prevention | https://www.cdc.gov/stroke/facts.htm

10. [National MS Society] National Multiple Sclerosis Society | https://www.nationalmssociety.org/What-is-MS/MS-FAQ-s

11. [Grand View Research, 2023] Grand View Research, Physical Rehabilitation Equipment Market Report | https://www.grandviewresearch.com/industry-analysis/physical-rehabilitation-equipment-market

12. [American Physical Therapy Association] American Physical Therapy Association | https://www.apta.org/your-career/careers-in-physical-therapy/workforce-data

13. [Journal of NeuroEngineering and Rehabilitation] Journal of NeuroEngineering and Rehabilitation | https://jneuroengrehab.biomedcentral.com/